Aptose Biosciences Inc., listed on the Nasdaq Stock Market under the symbol APTO, recently filed a Form 8-K report with the Securities and Exchange Commission. The report, dated January 13, 2025, indicated various key details about the company’s operations.
The Canadian-based biotechnology company, with its headquarters located in Toronto, Ontario, shared information stating its address at 66 Wellington Street West, Suite 5300, TD Bank Tower, Box 48, Toronto, Ontario, M5K 1E6, Canada. The phone number for the company was listed as (310) 849-8060.
The filing was duly signed by William G. Rice, Ph.D., President, and Chief Executive Officer of Aptose Biosciences Inc., on January 13, 2025.
This Form 8-K report provides essential information for investors and stakeholders of Aptose Biosciences Inc. regarding recent company developments and key operational aspects.
It’s imperative for interested parties to review the full filing on the SEC’s website for a comprehensive understanding of the details disclosed by Aptose Biosciences Inc.
This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Aptose Biosciences’s 8K filing here.
About Aptose Biosciences
Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.
Recommended Stories
- Five stocks we like better than Aptose Biosciences
- Dividend King Proctor & Gamble Is A Buy On Post-Earnings Weakness
- AI Demand Sparks Opportunities for These 3 Nuclear Energy Leaders
- What is Forex and How Does it Work?
- TSMC: Long-Term Outlook Still Strong as Geopolitical Risk Rises
- Find and Profitably Trade Stocks at 52-Week Lows
- Uber’s NVIDIA Deal and Buybacks Signal Major Upside
